- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07792408
Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.
연구 개요
상태
상세 설명
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Medical Information
- 전화번호: 617-341-6777
- 이메일: medicalinfo@vrtx.com
연구 장소
-
-
-
Montreal, 캐나다
- 모병
- Altasciences - Beaumont Clinic Montreal
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m^2), inclusive
- A total body weight of greater than (>) 50 kg
Key Exclusion Criteria:
- History of febrile illness within 5 days before the first dose of study drug
- Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of study drug
Other protocol defined Inclusion/Exclusion criteria will apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part A: VX-407 With Levonorgestrel/Ethinyl Estradiol (LNG/EE)
Participants will receive a single dose of LNG/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 every 12 hours (q12h) from Days 8 through 26 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
|
실험적: Part B (Optional): VX-407 With Norgestimate/Ethinyl Estradiol (NGM/EE)
Participants will receive a single dose of NGM/EE on Days 1 and 23 in fasted state. Participants will also receive VX-407 q12h from Days 10 through 30 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
|
실험적: Part C (Optional): VX-407 With Norethindrone/Ethinyl Estradiol (NET/EE)
Participants will receive a single dose of NET/EE on Days 1 and 19 in fasted state. Participants will also receive VX-407 q12h from Days 6 through 22 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
|
실험적: Part D (Optional): VX-407 With Drospirenone/Ethinyl Estradiol (DRSP/EE)
Participants will receive a single dose of DRSP/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 q12h from Days 8 through 26 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Part A: Maximum Observed Plasma Concentration (Cmax) of LNG/EE in the Absence and Presence of VX-407
기간: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
|
Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407
기간: From Day 1 up to Day 9 and Day 23 up to Day 31
|
From Day 1 up to Day 9 and Day 23 up to Day 31
|
|
Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of NET and EE in the Absence and Presence of VX-407
기간: From Day 1 up to Day 5 and Day 19 up to Day 23
|
From Day 1 up to Day 5 and Day 19 up to Day 23
|
|
Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of DRSP and EE in the Absence and Presence of VX-407
기간: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
|
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG/EE in the Absence and Presence of VX-407
기간: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
|
Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407
기간: From Day 1 up to Day 9 and Day 23 up to Day 31
|
From Day 1 up to Day 9 and Day 23 up to Day 31
|
|
Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of NET and EE in the Absence and Presence of VX-407
기간: From Day 1 up to Day 5 and Day 19 up to Day 23
|
From Day 1 up to Day 5 and Day 19 up to Day 23
|
|
Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of DRSP and EE in the Absence and Presence of VX-407
기간: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: From Day 1 up to Day 36
|
From Day 1 up to Day 36
|
|
Part B (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: From Day 1 Up to Day 39
|
From Day 1 Up to Day 39
|
|
Part C (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: From Day 1 up to Day 32
|
From Day 1 up to Day 32
|
|
Part D (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: From Day 1 up to Day 36
|
From Day 1 up to Day 36
|
|
Part A: Maximum Observed Plasma Concentration (Cmax) of VX-407
기간: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
|
Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
기간: Days 11, 17 and 23 up to Day 31
|
Days 11, 17 and 23 up to Day 31
|
|
Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
기간: Days 7, 13 and 19 up to Day 23
|
Days 7, 13 and 19 up to Day 23
|
|
Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
기간: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
|
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
기간: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
|
Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
기간: Days 11, 17 and 23 up to Day 31
|
Days 11, 17 and 23 up to Day 31
|
|
Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
기간: Days 7, 13 and 19 up to Day 23
|
Days 7, 13 and 19 up to Day 23
|
|
Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
기간: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- VX26-407-014
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .